Research progress in immune checkpoint inhibitor associated tuberculosis infection
10.3760/cma.j.cn371439-20241030-00109
- VernacularTitle:免疫检查点抑制剂相关结核感染研究进展
- Author:
Xunqi LIU
1
;
Jianghong AN
Author Information
1. 深圳市第三人民医院肿瘤内科，深圳 518112
- Keywords:
Neoplasms;
Immune checkpoint inhibitors;
Tuberculosis
- From:
Journal of International Oncology
2025;52(10):637-640
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, programmed death-1/programmed death-ligand 1 inhibitors, as representatives of immune checkpoint inhibitors (ICIs), have become an important advancement in the field of tumor therapy, significantly improving the survival and prognosis of tumor patients. However, immune-related adverse events associated with ICIs treatment pose challenges for clinical management. In particular, the emergence of active tuberculosis and reactivation of latent tuberculosis infection has attracted attention, and its mechanism may be closely related to the overactivation of the immune system and the changes of host-pathogen relationship. How to effectively predict and manage these adverse reactions has become a hot topic of current research.
